首页> 外文会议>International Congress on Coronary Artery Disease. >Pharmacological Reversal of Subcellular Remodeling in Heart Failure due to Myocardial Infarction
【24h】

Pharmacological Reversal of Subcellular Remodeling in Heart Failure due to Myocardial Infarction

机译:心肌梗死引起的心力衰竭亚细胞重塑的药理逆转

获取原文

摘要

In order to test if cardiac dysfunction and defects in subcellular organelles such as sarcoplasmic reticulum (SR), myofibrils (MF) and sarcolemma (SL) in heart failure are reversible, we treated the 12 weeks infarcted rats with or without prazosin (α-adrenoceptor blocker), metoprolol (β-adrenoceptor blocker) or losartan (angiotensin II receptor blocker) for 8 weeks. Cardiac dysfunction, as reflected by depressed +dP/dt and -dP/dt, as well as decreased SR Ca2+-uptake and SL Na+-K+ ATPase activities in 20 weeks infarcted animals were partially reversed by prazosin, metoprolol or losartan treatment. On the other hand, depressed SR Ca2+-release and MF Ca2+-stimulated ATPase activities in the failing hearts were not affected by prazosin, metoprolol or losartan treatment. These results suggest that partial improvement in cardiac dysfunction in heart failure due to myocardial infarction is associated with partial attenuation of SR and SL remodeling by treatment with prazosin, metaprolol and losartan.
机译:为了测试亚细胞功能障碍的心脏功能障碍和亚细胞内细胞素(SR),肌纤维(MF)和Sarcolemma(SL)中的缺陷是可逆的,我们将12周梗死的大鼠有或不含普拉索汀治疗(α-肾上腺素依赖者阻断剂),美容托洛尔(β-肾上腺素受体阻滞剂)或氯沙坦(血管紧张素II受体阻滞剂)8周。心脏功能障碍,如抑制+ DP / DT和-DP / DT的反射,以及20周内梗死的动物在20周内降低的SR CA2 + -UP + ATP酶活性被Prazosin,氟普罗尔或氯沙坦治疗部分反转。另一方面,抑制的SR Ca2 + -Release和MF Ca2 + -Stimulated在失败的心中不受普拉索辛,美容洛洛尔或氯沙坦治疗的影响。这些结果表明,由于心肌梗死引起的心力衰竭心力功能障碍的部分改善与SR和SL和SL重塑通过用Prazosin,Metaprolol和氯沙坦治疗的部分衰减相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号